Genovate Biotechnology Co., Ltd. (TPEX:4130)

Market Cap	2.14B
Revenue (ttm)	502.80M
Net Income (ttm)	18.61M
Shares Out	111.52M
EPS (ttm)	0.17
PE Ratio	115.33
Forward PE	n/a
Dividend	0.10 (0.52%)
Ex-Dividend Date	Aug 21, 2024

Volume	33,688
Average Volume	50,766
Open	19.15
Previous Close	19.15
Day's Range	18.95 - 19.20
52-Week Range	18.50 - 26.40
Beta	0.26
RSI	33.03
Earnings Date	Aug 11, 2025

About Genovate Biotechnology

Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well as cosmetics. The company was founded in 1982 and is based in Hsinchu City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1982
• Employees: 195
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4130

Financial Performance

In 2024, Genovate Biotechnology's revenue was 510.86 million, a decrease of -3.34% compared to the previous year's 528.51 million. Earnings were 25.70 million, a decrease of -12.40%.